Prescription medicine
Efbemalenograstim alfa Brand names: Ryzneuta
Efbemalenograstim alfa (Ryzneuta) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the efbemalenograstim alfa FDA label on DailyMed (effective May 19, 2026); every efbemalenograstim alfa label on DailyMed.
Highlights of the record
FDA label of May 19, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageINDICATIONS AND USAGE RYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Forms and strengths
- 20 mg/ml
Injection.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 37 through July 30, 2026
What is efbemalenograstim alfa used for?
From the label: indications and usageINDICATIONS AND USAGE RYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Limitations of Use RYZNEUTA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. […]
FDA pharmacologic class: Leukocyte Growth Factor.
Source: FDA drug label (RYZNEUTA), Acrotech Biopharma Inc, effective May 19, 2026 (SPL set 290ed754-758c-9cae-e063-6294a90ae68b), via openFDA; the full label on DailyMed
Is there a generic for efbemalenograstim alfa (Ryzneuta)?
No generic efbemalenograstim alfa is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the efbemalenograstim alfa label say about other medicines?
The efbemalenograstim alfa label names 3 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Eflapegrastim | warnings | RYZNEUTA is contraindicated in patients with a history of serious allergic reactions to RYZNEUTA or other rhG-CSF products such as pegfilgrastim, eflapegrastim or filgrastim products. |
| Filgrastim | contraindications | CONTRAINDICATIONS RYZNEUTA is contraindicated in patients with a history of serious allergic reactions to granulocyte stimulating factors such as efbemalenograstim alfa-vuxw, pegfilgrastim, or filgrastim products [see Warnings and Precautions ( 5.3 )]. |
| Pegfilgrastim | contraindications | CONTRAINDICATIONS RYZNEUTA is contraindicated in patients with a history of serious allergic reactions to granulocyte stimulating factors such as efbemalenograstim alfa-vuxw, pegfilgrastim, or filgrastim products [see Warnings and Precautions ( 5.3 )]. |
Source: FDA drug label (RYZNEUTA), Acrotech Biopharma Inc, effective May 19, 2026 (SPL set 290ed754-758c-9cae-e063-6294a90ae68b), via openFDA; the full label on DailyMed
What do FAERS reports show for efbemalenograstim alfa?
The FDA Adverse Event Reporting System holds 37 reports that list efbemalenograstim alfa among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 18 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other leukocyte growth factors
- the pharmacologic class, with prices and generics
- Efbemalenograstim alfa side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other